A Review of Salivary Biomarkers in Breast Cancer Publisher



Koopaie M¹ ; Fatahzadeh M² ; Kolahdooz S³ ; Mousavi R⁴
Source: Current Women's Health Reviews Published:2023

Abstract

Objectives: This study aimed to review the literature related to salivary biomarkers used to diagnose breast cancer or predict responses to therapy and its prognosis. Methods: Studies were eligible for inclusion if they had compared salivary diagnostics for breast cancer with the gold standard or other biomarkers. Six databases (PubMed, EMBASE, ScienceDi-rect, Scopus, Web of Science, and Ovid) and Google Scholar search engine searched for pertinent literature using specific search terms: breast cancer, diagnosis, prognosis saliva, and salivary bi-omarker. Of the 513 studies screened, 110 were selected for inclusion in this review. Different salivary biomarkers were classified and discussed. Results: Our analysis indicated that the sensitivity and specificity of salivary biomarkers, such as c-erb-B2 and sialic acid in BC detection are comparable with serum values. Salivary levels of autoan-tibodies against MUC1, CA 15-3, and adiponectin had a better correlation with breast cancer than serum levels. Assessment of biomarkers, such as HER-2, helps develop a treatment plan and evalu-ates response to treatment. Conclusion: Our study confirms that salivary biomarkers are becoming increasingly important in breast cancer diagnosis and treatment planning, as well as in predicting therapeutic response and prognosis. Salivary biomarkers such as c-erb-B2 in association with traditional criteria offer the promise of use as a noninvasive screening method for breast cancer. Additional studies are warrant-ed to determine the most sensitive and specific salivary biomarkers for this purpose. © 2023 Bentham Science Publishers.